Tralokinumab-ldrm is approved for the treatment of moderate-to-severe AD in adult and adolescent patients 12 years and older in the European Union, Canada, Great Britain, the United Arab Emirates, ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

A 94-year-old man presented with painful leg ulcers that were affecting his mobility. No clear history of these ulcers was obtained on admission or during his initial 7 days of admission and there was ...

Pyoderma gangrenosum lesion regression after dapsone treatment. However, after two weeks, the patient’s hematological condition deteriorated, presenting with a hemoglobin level of 7 g/dL, white blood ...

Department of Internal Medicine, Dermatology and Allergology, the Specialist Hospital, Zabrze, Poland Department of Dermatology in Zabrze, Silesian Medical University in Katowice, Poland Pyoderma ...

Department of Internal Medicine, Dermatology and Allergology, the Specialist Hospital, Zabrze, Poland Department of Dermatology in Zabrze, Silesian Medical University in Katowice, Poland ...

Pyoderma gangrenosum is a rare, inflammatory, chronic and recurrent disease of unknown etiology, characterized by noninfectious, necrotizing and painful cutaneous ulcers. Usually it affects adults ...

Granulomatosis with polyangiitis (GPA) is a small-to-medium vessel vasculitis that can affect the skin, respiratory tract, kidneys and other organs. A rare cutaneous manifestation of GPA is pyoderma ...

The physicians observed significant improvement over the next week with epithelization rates beyond 50% by week 7. A case of a patient with a rare combination of myelofibrosis (MF) and pyoderma ...

In a lecture at VMX, Jason B. Pieper, DVM, MS, DACVD, outlined the next steps in the treatment of pyoderma in dogs when the infection is non-responsive to topical therapy Recommendations for systemic ...